Eli Lilly shares trade sideways as Foundayo launches with strong initial prescriptions: weekly report

Traders Union
All News
Financial News
Eli Lilly slips 1.02% this week

Highlights

Eli Lilly trades in a short-term downtrend, positioned above medium-term support but below key resistance levels.
Technical momentum remains weak with dominant selling, as most oscillators and indicators flash bearish or oversold readings.
Price action is likely to range between $870 and $965 over the next week, with a low probability of reversal.

Regulatory scrutiny and strong Foundayo launch shape sentiment this week

Eli Lilly is facing renewed regulatory scrutiny after the FDA requested more data on its newly approved obesity pill due to potential liver injury and also mandated post-marketing cardiovascular studies. The company's recently launched oral GLP-1 drug, Foundayo, saw an encouraging 1,390 prescriptions in its first week, signaling strong initial demand. Institutional activity continues, with Whittier Trust Co. increasing its stake by 26.6% in the fourth quarter. There is also ongoing discussion in the market regarding potential pricing challenges from new, lower-cost GLP-1 programs introduced by competitors.

Oversold readings and mixed momentum signal weak near-term outlook over week

On the weekly chart, LLY trades between $883.00 and $929.91, with volatility at 5.31%. Momentum remains mixed as the MACD and ADX provide neutral readings, but the weekly RSI continues to signal a Sell, and both the Bull/Bear Power and CCI are deeply oversold. The stock holds above its MA-50 but is notably below both the recent peak and the MA-20, highlighting near-term weakness despite long-term strength above the MA-200. Weekly oscillators overall remain bearish, with oversold signals from the Stochastic RSI and divergence in some short-term readings, suggesting a pause in the downtrend is possible but a reversal remains unlikely.

Sideways movement expected as rebound probability remains low next week

Over the next 5 trading days, LLY is expected to remain in a range between $870 and $965, with a sideways scenario being most likely according to W1 indicators. The probability of a rebound above $965 is low, with less than a 20% chance, given that none of the four key indicators suggest a buy. If buyers regain control, a retest of the upper range is possible, but a drop below $870 could lead to extended declines toward dynamic support near the MA-50.

Anton Kharitonov, expert at Traders Union, notes that Eli Lilly (LLY) has shown persistent weakness this week, closing well below the key MA-20 and struggling to regain upward momentum. He sees ongoing regulatory scrutiny and new competitive threats adding to a cautious outlook, even as early demand for Foundayo and institutional buying provide some support. The stock remains above its MA-50, but indicators like RSI, CCI, and Bull/Bear Power are all bearish, signaling continued pressure. Kharitonov believes sideways trading between $870 and $965 is the most likely scenario for the coming week, with little evidence of an imminent rebound. He stays watchful for a move below $870, which could trigger further selling. "Unless buyers can reverse the sentiment and push price above $965, the risks remain tilted to the downside for LLY this week."

Previously it was reported that Eli Lilly shares were under persistent bearish momentum amid regulatory uncertainty and ongoing portfolio expansion. The latest technical signals reinforce this cautious stance, with traders advised to monitor the $870 level for signs of renewed downside risk if near-term support is breached.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.